The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
XOSPATA (Astellas Pharma Australia Pty Ltd)
Product name
XOSPATA
Date registered
Evaluation commenced
Decision date
Approval time
151 working days (255)
Active ingredients
gilteritinib fumarate
Registration type
NCE/NBE
Indication
XOSPATA (film coated tablets) is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation.